Uptake of the Biologic Filgrastim and Its Biosimilar Product Among the Medicare Population

Abstract

Uptake of the Biologic Filgrastim and Its Biosimilar Product Among the Medicare Population Biologic pharmaceuticals are complex, high-cost therapeutics used to treat severe and chronic conditions. 1 Biosimilar biological products can increase access to therapy and lower health care costs. The development and approval of biosimilar biologics in the United States was made possible by the Biologics Price Competition and Innovation Act passed in 2010. As of June 1, 2018, 10 biosimilars had been approved by the US Food and Drug Administration (FDA). These products share multiple indications for neutropenia and malignancy. Tbo-filgrastim (Granix), a stand-alone alternative biologic with a single indication, was also evaluated.